ID   PC-1 [Human lung carcinoma]
AC   CVCL_S978
SY   PC 1; PC1
DR   EFO; EFO_0002842
DR   Cosmic; 1089227
DR   Cosmic; 1571733
DR   Cosmic; 2645027
DR   IARC_TP53; 11869
DR   IARC_TP53; 21086
DR   Wikidata; Q54938382
RX   PubMed=758928;
RX   PubMed=1847845;
RX   PubMed=3731100;
RX   PubMed=8385084;
RX   PubMed=10536175;
RX   PubMed=11583962;
RX   PubMed=12794755;
RX   PubMed=17511773;
CC   From: Immuno-Biological Laboratories (IBL); Tokyo; Japan.
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly334Val (c.1001G>T); Zygosity=Unspecified (PubMed=10536175).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 19-12-24; Version: 17
//
RX   PubMed=758928; DOI=10.1038/bjc.1979.3; PMCID=PMC2009802;
RA   Kinjo M., Oka K., Naito S., Kohga S., Tanaka K., Oboshi S., Hayata Y.,
RA   Yasumoto K.;
RT   "Thromboplastic and fibrinolytic activities of cultured human cancer
RT   cell lines.";
RL   Br. J. Cancer 39:15-23(1979).
//
RX   PubMed=1847845; DOI=10.1007/BF00685110;
RA   Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T.,
RA   Saijo N.;
RT   "Prediction of the antitumor activity of new platinum analogs based on
RT   their ex vivo pharmacodynamics as determined by bioassay.";
RL   Cancer Chemother. Pharmacol. 27:263-270(1991).
//
RX   PubMed=3731100;
RA   Hanai N., Shitara K., Yoshida H.;
RT   "Generation of monoclonal antibodies against human lung squamous cell
RT   carcinoma and adenocarcinoma using mice rendered tolerant to normal
RT   human lung.";
RL   Cancer Res. 46:4438-4443(1986).
//
RX   PubMed=8385084; DOI=10.1111/j.1349-7006.1993.tb02851.x; PMCID=PMC5919128;
RA   Suzuki S., Takahashi T., Nakamura S., Koike K., Ariyoshi Y.,
RA   Takahashi T., Ueda R.;
RT   "Alterations of integrin expression in human lung cancer.";
RL   Jpn. J. Cancer Res. 84:168-174(1993).
//
RX   PubMed=10536175; DOI=10.3892/ijo.15.5.927;
RA   Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.;
RT   "Comprehensive analysis of p53 gene mutation characteristics in lung
RT   carcinoma with special reference to histological subtypes.";
RL   Int. J. Oncol. 15:927-934(1999).
//
RX   PubMed=11583962; DOI=10.1016/S0002-9440(10)62521-7; PMCID=PMC1850523;
RA   Haruki N., Harano T., Masuda A., Kiyono T., Takahashi T.,
RA   Tatematsu Y., Shimizu S., Mitsudomi T., Konishi H., Osada H.,
RA   Fujii Y., Takahashi T.;
RT   "Persistent increase in chromosome instability in lung cancer:
RT   possible indirect involvement of p53 inactivation.";
RL   Am. J. Pathol. 159:1345-1352(2001).
//
RX   PubMed=12794755; DOI=10.1002/ijc.11184;
RA   Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T.,
RA   Mitsudomi T.;
RT   "RASSF1A gene inactivation in non-small cell lung cancer and its
RT   clinical implication.";
RL   Int. J. Cancer 106:45-51(2003).
//
RX   PubMed=17511773; DOI=10.1111/j.1349-7006.2007.00507.x; PMCID=PMC11159702;
RA   Fukuyama T., Ichiki Y., Yamada S., Shigematsu Y., Baba T., Nagata Y.,
RA   Mizukami M., Sugaya M., Takenoyama M., Hanagiri T., Sugio K.,
RA   Yasumoto K.;
RT   "Cytokine production of lung cancer cell lines: correlation between
RT   their production and the inflammatory/immunological responses both in
RT   vivo and in vitro.";
RL   Cancer Sci. 98:1048-1054(2007).
//